Biocon Q1FY23 revenue up 23% at Rs 2,217 cr
We have a strong start for this year. At the consolidation rate, Yoy’s income grew 23 percent supported by strong growth in both biosimilar (29 percent) and generic (19 percent). Core income before interest, tax, depreciation, and amortization (EBITDA) grew 25 percent and margin increased to 31 percent compared to […]
Continue Reading